Background & Aims No adjuvant therapy has been shown to extend the survival of patients
with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether
injections of activated cytokine-induced killer (CIK) cells (CD3+/CD56+ and CD3+/CD56-T
cells and CD3-/CD56+ natural killer cells) prolongs recurrence-free survival of patients after
curative therapy for HCC. Methods We performed a multicenter, randomized, open-label,
phase 3 trial of the efficacy and safety of adjuvant immunotherapy with activated CIK cells …

Background Cytokine-induced killer cells have been used as an adjuvant treatment for
hepatocellular carcinoma with curative treatment. However, the outcomes remain
controversial. Aim We conducted this meta-analysis to assess the safety and efficacy of
cytokine-induced killer cells. Methods Randomized controlled trials on cytokine-induced
killer cells for hepatocellular carcinoma after curative treatments were identified by electronic
searches. A meta-analysis was carried out to examine disease-free survival, overall survival …